Animal-free in vitro
The aim of the Challenge is to adapt established Organisation for Economic Development (OECD) Test Guideline (TG) in vitro assays so that they are free from animal-derived products, delivering a robust, human-relevant (and preferably chemically-defined) version of the assays that demonstrates improved data quality and reproducibility.
Challenges briefing webinar
View the Challenges briefing webinar recording to find out more about this Challenge.
Phase 2 awarded
A team led by Dr Victoria Hutter, ImmuOne Ltd has been awarded £1 million to deliver the project: Establishing in vitro OECD test guidelines assays (TG487 and TG455) free from animal-derived products.
Phase 1 awarded
Three Phase 1 Awards were made to project teams led by:
- Prof. Dr. Henner Hollert and Dr Andreas Schiwy, Goethe University Frankfurt, £99,647.
- Dr Victoria Hutter, ImmuONE Ltd, £99,650.
Dr Carol Treasure, XCellR8 Ltd, £99,932.
Sponsored by Unilever and AstraZeneca, and co-funded by Unilever, this Challenge aims to adapt established Organisation for Economic Development (OECD) Test Guideline (TG) in vitro assays so that they are free from animal-derived products, delivering a robust, human-relevant (and preferably chemically-defined) version of the assays that demonstrates improved data quality and reproducibility.
The OECD Guidelines for the Testing of Chemicals are the international standard for assessing the potential effects of chemicals on human health and the environment. The Guidelines are regularly expanded and updated to ensure they reflect the state-of-the-art science and techniques to meet member countries regulatory needs. A growing number of in vitro assays are included in the Guidelines that can be used as alternatives to animal studies (European Commission, Joint Research Centre 2019). There is increasing interest for these assays to also be free from animal-derived products to improve human relevance and reproducibility, and to reduce the use of animals (Gstraunthaler et al., 2013). This was highlighted during a joint NC3Rs/Unilever workshop ‘Towards the development of animal product free in vitro systems’ that was held in January 2020.
Animal-derived serum, especially foetal bovine serum (FBS), is widely used in in vitro assays as a supplement in cell culture media to support cell growth, but its production has animal welfare concerns and its use impacts on the reproducibility of experiments due to inherent batch-to-batch variation (van der Valk et al., 2018). The complete composition of FBS is not known. The presence of animal-derived serum can alter the biological response of some human cell types causing further issues with the relevance of the data generated (Shahdadfar et al., 2005; Usta et al., 2014). Use of human serum has been successful in some assays (Belot et al., 2017), but its use in standard laboratory testing environments is limited by ethical concerns and availability (Jacobs et al., 2019), driving the need for the development of chemically-defined media for use in in vitro assays.
It is increasingly recognised that knowledge of all the constituents of the cell culture medium used and their influence on cellular processes are important for improved experimental reproducibility (Baker, 2016; Hirsch and Schildknecht 2019). Chemically-defined media is completely free from serum (both animal and human-derived) and all the chemical components and concentrations are known, eliminating any ethical and scientific quality issues resulting from the use of animal or human-derived components. However, while there have been successful studies using chemically-defined media (Usta et al., 2014), it is technically very challenging, for example, to ensure it includes all the required components for a cell type (van der Valk et al., 2010; van der Valk et al., 2018).
Other components used in in vitro assays that are animal-derived also provide scientific and welfare concerns. Sources of metabolism include the use of liver fractions from the rat (S9 fraction). While these are cheap, readily available and provide a sustained source of metabolic activity, the complete composition of these fractions is not known and there are significant differences in liver metabolism between rodents and humans. For example, humans differ from rodents in isoform composition, expression and catalytic activities of enzymes involved in drug metabolism, including Cytochrome P450s (Williams, 1974), reducing the reliability of extrapolating metabolism data from animal models to humans.
The majority of antibodies used in in vitro assays are generated using animals. Animal-derived antibodies have significant drawbacks, they are expensive and unstable, have variable specificity and can suffer from batch-to-batch variation, adversely affecting the reproducibility of research (Bradbury and Plückthun 2015). Non-animal-derived antibodies and affinity reagents are mature technologies that are commercially available, amenable to most research applications and can offer significant scientific benefits (Gray et al., 2016). This was highlighted in a recent review from the EURL ECVAM Scientific Advisory Committee, which concluded non-animal-derived antibodies can replace animal-derived antibodies in most laboratory applications (Viegas Barroso et al., 2020). Uptake of non-animal-derived antibodies however has been slow with issues such as initial costs and a lack of awareness within the scientific community acting as barriers to their wide uptake (Groff et al., 2020).
In this Challenge, an established in vitro assay with an approved OECD TG, is required to be modified to remove animal-derived reagents whilst still generating scientifically robust and reproducible data.
Using an established OECD TG provides the opportunity to compare the performance of the newly established assay with the current assay using the positive and negative controls and performance criteria outlined in the Guideline. The OECD TGs selected for animal-free modification are in the areas of genotoxicity and reproductive toxicity:
- In Vitro Mammalian Cell Micronucleus Test OECD TG487: For this Guideline, the focus will be on the use of human-derived cells (human peripheral blood lymphocytes or a human cell line, for example, TK6 cells), development of culture conditions avoiding the use of animal-derived components and the replacement of animal-derived S9 fractions as a source of exogenous metabolism. Otherwise the assay must meet the requirements of the Guideline, allowing short and long-term treatment and metabolic activation of pro-mutagens. Performance assessment will ultimately rely on the output of the assay based on its performance with suitable positive and negative controls.
- Performance-Based Test Guideline for Stably Transfected Transactivation In Vitro Assays to Detect Estrogen Receptor Agonists and Antagonists OECD TG455: For this guideline the focus will be on the use of human-derived cells expressing the human estrogen receptor (e.g. ER-CALUX, ERα-HeLa-9903, VM7Luc4E2) and development of culture conditions avoiding the use of animal-derived components (ideally focusing on chemically-defined medium). Performance assessment will ultimately rely on the output of the assay based on its performance with suitable positive and negative controls.
One, or preferably both TGs, should be addressed in this Challenge. These assays are used across industries including the fast-moving consumer goods and pharmaceutical industries which will help drive their broad uptake. In addition, the components will be transferable to other assay types, increasing the toolbox of animal-free assays in the future. For example, an alternative source of metabolic activation to the standard rat-derived S9 fraction will be valuable in a wide range of in vitro assays such as metabolic stability screening and intrinsic clearance and metabolism.
Successful completion of this Challenge will deliver an adapted protocol free from animal-derived products based on the original OECD TG that generates data of comparable or higher quality (due to being both more human-relevant and reproducible) and which can be transferred to other laboratories to facilitate industry uptake. Although acceptance of the animal free-protocols by OECD falls outside the scope of the Challenge, some early interaction with UK authorities, to ensure potential for progression towards the OECD work programme and future acceptance as an Annex to the current OECD TG, is an expected deliverable throughout Phase 2 of the Challenge.
A number of components of in vitro assays are currently derived from animal sources. These include:
- Metabolic Enzymes: The provision of sources of metabolism for in vitro assays are mostly obtained from rat livers (Hubbard et al., 1985). Rats are dosed with a substance such as Aroclor or phenobarbital to induce increased levels of liver metabolism before being killed and an S9 fraction of their liver collected, which is then added to assays.
- Antibodies: An estimated one million animals are used per year in the EU alone for antibody production (Viegas Barroso et al., 2020). Antibodies generated for use in research are often made by inoculating animals with the protein of interest along with an adjuvant to increase the immune response. Blood is then collected from the animals and their antibodies generated in response to the protein of interest isolated. Production typically involves the immunisation of between up to three animals (usually mice or rabbits, but sometimes sheep, chickens, goats or donkeys) per target. Additionally, multiple attempts are often needed to generate antibodies for certain targets, further increasing animal use.
- Serum: Collection of serum, and specifically FBS, is a by-product of the dairy industry where blood is collected from the unborn unanaesthetised calf by a cardiac puncture. Recent estimates state approximately 600,000 litres of FBS are produced annually worldwide, corresponding to two million bovine foetuses (Brindley et al., 2012 and van der Valk 2020).
Currently, assays carried out in OECD TG455 and TG487 use and/or contain a number of animal-derived products. If successful, this Challenge could lead to the acceptance of new protocol(s) in the OECD TGs that are free from animal-derived products, whilst also improving their human-relevance and robustness. More generally improved in vitro assays would be relevant to a range of industrial sectors including those where animal testing is not conducted (e.g. cosmetics) and those where in vitro assays are important screens prior to animal testing (e.g. pharmaceuticals).
Full Challenge information
Review Panel membership
|Dr Ian Ragan (Chair)||Independent|
|Dr Andrew Scott (Sponsor)||Unilever|
|Dr Ann Doherty (Sponsor||AstraZeneca|
|Dr Jo Elloway (Sponsor)||AstraZeneca|
|Professor Emanuela Corsini||University of Milan|
|Professor Jason Gill||University of Newcastle|
|Dr Miriam Jacobs||Public Health England|
|Dr Marloes Peeters||University of Newcastle|
|Dr Martino Picardo||Independent|
|Professor Simon Reed||University of Cardiff|
|Professor Jan Van der Valk||University of Utrecht|
|Prof. Dr. Mathieu Viken||Vrije Universiteit Brussel|